Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lexapro (escitalopram) Clear all
Completed Phase 4 Interventional Results available

Connectivity Affecting the Antidepressant REsponse Study

NCT02332291
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Functional Dyspepsia Treatment Trial

NCT00248651
View directory record Official record
Conditions
Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions
Amitriptyline, Escitalopram, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 24, 2026, 4:29 AM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Citalopram for Cocaine Dependence

NCT01535573
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Joy Schmitz
Other
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 24, 2026, 4:29 AM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 24, 2026, 4:29 AM EDT
Recruiting Phase 1 Interventional

Pattern Separation in Major Depressive Disorder

NCT07139834
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
Drug
Lead sponsor
Jeffrey Miller
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Sep 24, 2026, 4:29 AM EDT
Terminated Phase 2 Interventional Results available

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

NCT05289830
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Periampullary Cancer
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 24, 2026, 4:29 AM EDT
Not listed Phase 1 Interventional

Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)

NCT01753882
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Lexapro, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 4 Interventional

Ethnic Variations in Antidepressant Response

NCT00047671
View directory record Official record
Conditions
Depression
Interventions
Citalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2009 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Does Dual Therapy Hasten Antidepressant Response?

NCT00519428
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
escitalopram, bupropion extra long (XL), escitalopram + bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Not applicable Interventional

PACEPro - Mood Management Pilot

NCT00416221
View directory record Official record
Conditions
Depression
Interventions
Lexapro, an antidepressant medicine, Physical Activity, Mood Management Skills, Personalized support from a Family Nurse Practitioner
Drug · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Treating Negative Affect in Low Back Pain Patients

NCT04747314
View directory record Official record
Conditions
Chronic Low Back Pain, Negative Affectivity
Interventions
Antidepressant, Enhanced Fear Avoidance Rehabilitation
Drug · Other
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

A Study Utilizing Escitalopram in Glioma Patients

NCT03728673
View directory record Official record
Conditions
Glioma of Brain, Glioma
Interventions
Escitalopram Oral Capsules
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 24, 2026, 4:29 AM EDT
Terminated Phase 4 Interventional Results available

Neurobiological Bases of Placebo Response in Major Depressive Disorder

NCT01787240
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Depression and Self-care in Heart Failure

NCT01028625
View directory record Official record
Conditions
Heart Failure, Depression
Interventions
Cognitive Behavior Therapy, Heart Failure Self-care Education
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Sep 24, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome of Depression & Treatment Response to Citalopram

NCT02330068
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
citalopram
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

NCT00564278
View directory record Official record
Conditions
Depression
Interventions
Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

NCT00556140
View directory record Official record
Conditions
Psychotic Depression
Interventions
Aripiprazole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 24, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.

NCT00211770
View directory record Official record
Conditions
Autism
Interventions
Behavioral Assessment
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Sep 24, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

NCT02553161
View directory record Official record
Conditions
Depression, Anxiety, Bipolar Disorder
Interventions
Escitalopram, Cognitive behavioral Psychotherapy
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Stanford, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 24, 2026, 4:29 AM EDT